Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Total Non-current Liabilities
All obligations due after more than one year.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities broadly unchanged from a year ago
Total non-current liabilities stood at $470.1M at the end of Q1 FY2026, down 1.9% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.
Context
- Total non-current liabilities amounted to 101.6% of total assets at the end of Q1 FY2026, down 46.3 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -1.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 467.04M USD
- Year-over-year change
- -4.0%
- 4-year CAGR
- -1.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 467.04M | -4.0% |
| FY2024 | 2024-12-31 | 486.31M | -3.6% |
| FY2023 | 2023-12-31 | 504.57M | +5.2% |
| FY2022 | 2022-12-31 | 479.41M | -5.1% |
| FY2021 | 2021-12-31 | 505.18M | — |
Total Non-current Liabilities vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.9% is the 6th highest of 10, against a peer median of -1.0%.
- Total non-current liabilities amounts to 101.6% of total assets for ESPR, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $648.6M USD | -14.8% | +6.5% | 49.1% | |
| Mar 2026 | $470.1M USD | -1.9% | -0.9% | 101.6% | |
| Mar 2026 | $290.38M USD | +31.6% | +82.0% | 32.8% | |
| Mar 2026 | $249.7M USD | +127.0% | +7.6% | 73.0% | |
| Mar 2026 | $143.43M USD | -1.0% | +2.5% | 101.6% | |
| Mar 2026 | CA$140.21M CAD | +16.0% | +0.1% | 10.7% | |
| Mar 2026 | $3.59M USD | -43.6% | -37.0% | 1.8% | |
| Mar 2026 | $3M USD | +2339.0% | +25.6% | 0.6% | |
| Mar 2026 | $2.61M USD | -16.8% | -7.6% | 1.2% | |
| Mar 2026 | $406K USD | -51.3% | -27.0% | 0.2% | |
| Peer median (excluding ESPR) | — | -1.0% | +2.5% | 10.7% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 208.89M | 124.78M | 82.25M | 144.76M | 167.85M |
| Short-term Investments | 50.44M | 42.09M | 0 | 0 | 0 |
| Net Receivables | 22.93M | 33.73M | 48.49M | 80.14M | 140.19M |
| Inventory | 34.39M | 35.2M | 65.62M | 94.49M | 105.12M |
| Other Current Assets | 11.17M | 9.87M | 4.51M | 18.02M | 4.5M |
| Total Current Assets | 328.97M | 246.68M | 201.07M | 338M | 462.57M |
| Property, Plant & Equipment (Net) | 2.56M | 1.2M | 4.68M | 5.77M | 3.26M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 56K | 56K | 56K | 56K | 56K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 417.85M |
| Other Non-current Assets | 50M | 0 | 0 | 0 | (123.13M) |
| Total Non-current Assets | 52.62M | 1.26M | 4.73M | 5.82M | 298.03M |
| Total Assets | 381.59M | 247.94M | 205.8M | 343.82M | 465.89M |
| Account Payables | 17.56M | 23.04M | 31.72M | 51.65M | 65.07M |
| Short-term Debt | 12.69M | 25.14M | 34.83M | 102.16M | 89.7M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.68M | 3.51M | 25.4M | 8.52M | 34.48M |
| Other Current Liabilities | 8.81M | 9.05M | 49.24M | 12.74M | 9.84M |
| Total Current Liabilities | 73.35M | 92.31M | 156.22M | 246.23M | 300.81M |
| Long-term Debt | 258.28M | 259.9M | 501.55M | 483.74M | 457.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 634K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 245.74M | 218.85M | 239.95M | 246.02M | 8.74M |
| Total Non-current Liabilities | 505.18M | 479.41M | 504.57M | 486.31M | 467.04M |
| Total Liabilities | 578.53M | 571.72M | 660.79M | 732.54M | 767.85M |
| Common Stock | 61K | 75K | 118K | 196K | 245K |
| Retained Earnings | (1.11B) | (1.34B) | (1.55B) | (1.6B) | (1.62B) |
| Accumulated OCI | (31K) | (2K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (196.94M) | (323.78M) | (454.99M) | (388.72M) | (301.97M) |
| Total Debt | 260.2M | 260.95M | 540.95M | 591.21M | 548M |
| Net Debt | 51.3M | 136.17M | 458.7M | 446.45M | 380.15M |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.